Get started
AEON Biopharma, Inc.AEON Biopharma, Inc.AEON Biopharma, Inc.

AEON Biopharma, Inc.

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals

AEON fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

AEON Biopharma, Inc. is a biopharmaceutical company. It engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

AEON does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company